Eli Lilly, the maker of Zepbound and Mounjaro, said its experimental GLP-1 pill successfully helped adults with obesity lose weight in a Phase 3 trial, as the company moves closer to submitting the drug for approval from the Food and Drug Administration.

In a news release Thursday, the drugmaker said the oral medication, called orforglipron, helped adults lose an average of 27.3 pounds in a 72-week trial.

The pill showed "significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies," the release added.

The results shared by Eli Lilly, which have not been peer reviewed and published as of Thursday morning, are "on par with what we see with the injectable forms of these drugs," Dr. Céline Gounder, CBS News medical contributor and editor-at-l

See Full Page